| INTRODUCTION
Infiltration of varied immune cell populations within the tumor microenvironment is increasingly being linked to clinical outcomes in cancer. Recent studies have demonstrated the important roles of tumor infiltrating immune cells in promoting tumor growth, metastasis, and resistance to therapy. [1] [2] [3] [4] [5] Therefore, the ability to accurately characterize the immune cell composition of tumors is important for both prognostic evaluation and to delineate the molecular mechanisms that underlie the function of tumor infiltrating leukocytes to ultimately aid in identifying potential therapeutic targets.
To date, characterizing immune cell populations within tumors has primarily relied on mRNA leukocyte signatures. [6] [7] [8] However, microRNAs (miRNAs), a class of small noncoding RNA molecules that post-transcriptionally regulate gene expression, have also been shown to play important roles in immune cell recruitment and activation. 9, 10 Prior work indicates that miRNAs are differentially expressed in many types of immune cells, and that cancerous immune cells show differential expression of miRNAs relative to their noncancerous counterparts, with some miRNAs even possessing tumor suppressor or oncogenic properties. [11] [12] [13] These results suggest that miRNAs could be used to characterize immune cell infiltration in tumors, and likely complement the information obtained from using mRNA-based signatures alone. Moreover, such characterization could also help to hone in on miRNA related mechanisms that dictate the balance between pro-and anti-tumor signals in the tumor microenvironment.
A significant challenge of currently available methods for miRNA profiling of immune cells is isolating sufficient numbers of leukocyte subsets for expression profiling, particularly in diseased patient samples such as tumors. Furthermore, while high throughput sequencing-based miRNA profiling has improved upon the sensitivity of first-generation miRNA assays, decoding the abundance of sequencing information into translatable and biologically relevant miRNA profiles remains a challenge in both in vitro and in silico approaches. 14 In light of this, we have developed a computational method to first derive miRNA signature profiles for different leukocyte subsets from tumor samples, and then integrate miRNA and mRNA leukocyte signatures to predict prognosis in breast and ovarian cancers, two cancers for which comprehensive genomic as well as clinical information is available through The Cancer Genome Atlas (TCGA).
| MATERIALS AND METHODS

| Genomic data and clinical information
Preprocessed TCGA breast invasive carcinoma (BRCA) and ovarian serous cystadenocarcinoma (OV) datasets were downloaded from the UCSC Xena Browser. 15 For mRNA data, we used normalized RNA-seq data (polyA+ Illumina HiSeq) for the breast cancer dataset and normalized gene expression array data (Affymetrix HGU133A) for the ovarian cancer dataset as they contained the most number of samples for their respective cancer types compared to the other gene expression profiling formats. Both datasets also comprise miRNA expression (Illumina HiSeq) data and overall time-to-event survival information.
Only samples obtained from tumors of patients were retained for the analysis. More details about the datasets are shown in Supporting Information Table S1 .
2.2 | Construction of miRNA leukocyte signatures in breast and ovarian cancer Information Table S2 for the leukocyte subsets that were retained for each cancer type).
While CIBERSORT uses purified mRNA immune cell signatures that are relatively well-established and accessible, few miRNA profiles of immune cell subsets have been assembled, with none profiled under tumor states to our knowledge. Given the key role of miRNAs in immune cell differentiation and regulation, we used a computational method to construct miRNA leukocyte profiles from the breast and ovarian cancer datasets.
Using the inferred fractions of immune cell infiltration in each sample and their corresponding miRNA expression data, we constructed a system of linear equations AX = B to determine the miRNA profiles of the leukocytes subsets for each cancer type. Here A is a matrix in which each row encodes the fraction of immune cells in each FIGURE 1 Schematic of approach. We first inputted mRNA expression data from patient tumor samples and a reference leukocyte mRNA signature matrix (named LM22) into CIBERSORT to infer immune cell composition in the samples. Next, we applied a constrained regression model to determine miRNA leukocyte profiles based on miRNA expression from the same set of patient samples. We further selected a subset of miRNAs from these signatures through differential expression analysis to construct a refined signature matrix that we then used to estimate immune cell infiltration in the tumor samples [Color figure can be viewed at wileyonlinelibrary.com] patient sample based on CIBERSORT's deconvolution method using CIBERSORT's own LM22 mRNA leukocyte signature matrix, whereas each column represents a leukocyte subset that had nonzero values in greater than 75% of the patient samples. The corresponding rows in matrix B contain the patient sample's miRNA expression levels, and X is the (unknown) miRNA leukocyte signature matrix. Each column in X is a specific miRNA and each row is a different leukocyte subset.
To compute X, an initial approach is to use the pseudo-inverse and set X = (A T A)
However, this solution results in several negative values for miRNA levels which is not biologically feasible, so we instead solved the following constrained optimization problem:
In other words, our goal is to retrieve the best values for X that are strictly non-negative. This optimization process was performed using the Limited-memory-Broyden-Fletcher-Goldfarb-Shanno (L-BFGS-B) algorithm through the "optim" function in R's core "stats"
package. 16 Briefly, the L-BFGS-B algorithm is a limited-memory quasiNewton method for solving large optimization problems with simple bounds on the variables. 17 After initialization with a starting point and boundary constraints, the objective function is approximated by a quadratic model at the point x k in the k-th iteration:
in which g k is the gradient at point x k and B k is the BFGS approximation to the Hessian matrix, which is updated by matrix addition at each iteration instead of being entirely recomputed, saving considerable computation time. We constrained all miRNA leukocyte expression values to be non-negative, resulting in matrix X, which denotes the expression level of all miRNAs for each leukocyte subset in the sample.
To test the impact of such a constraint, we compared the error (Euclidian distance between the reconstructed and observed expression profile for each tumor sample) obtained in the constrained and unconstrained version of the deconvolution method. With the unconstrained miRNA leukocyte signature matrix X, the constrained (non-negative) miRNA leukocyte signature matrix X + A, and the patient samples' miRNA expression levels B, we computed the proportional increase in reconstruction error e:
A low error e indicates that the non-negativity constraint imposes a low degree of distortion.
While we can directly use the matrix obtained from the constrained optimization method in our analysis, prior work has
shown that constructing a matrix with fewer miRNAs that are both representative (highly expressed in some cell types) and discriminative (differentially expressed between cell types) leads to a greater signalto-noise ratio and a faster computational run time. 6 To obtain such miRNA signature matrices, we minimized an inherent matrix property called the condition number, which measures the stability of the linear system to input variation or noise. 8, 18 Following Newman et al. 6 we assessed signature matrix stability via the 2-norm condition number using the "kappa" function in R, which is equal to the ratio of the largest to smallest nonzero singular values of a matrix, and sought to minimize this value.
A requirement for performing the condition number minimization algorithm is ranking the miRNAs for each immune cell type. While we can rank them based on expression levels, such ranking does not differentiate between miRNAs that are unique to specific cell types and those that are highly expressed in all cell types. As noted above, uniqueness is an important attribute for the signature matrix. To rank miRNAs for each of the immune cell types in our signature matrices, we computed their significance using the following function:
in which L is the set of leukocytes, x ℓ is the expression level of a specific miRNA in a leukocyte subset ℓ2L, μ is the average expression level of that particular miRNA in the other leukocytes Lnℓ, and σ is the SD of the miRNA expression level in the other leukocytes Lnℓ. Essentially, a z score was derived for each miRNA from which its cumulative probability was calculated. The miRNAs were then ranked based on their probability value in each leukocyte subset. The top 50 ranked miRNAs for each leukocyte subset are listed in Supporting Information Table S3 for the breast cancer data and Supporting Information Table S4 for the ovarian cancer data.
Following Newman et al. 6 the top G marker miRNAs from each immune cell type were combined into a signature matrix. We iterated G from 10 to 100 and retained the signature matrix with the lowest condition number. For the breast cancer data, we retained the signature matrix with condition number 13.6 at iteration G of 17. For the ovarian cancer data, we retained the signature matrix with condition number 17.3 at iteration G of 10.
| Prognostic analysis of leukocyte subsets
The association of immune cell infiltration and survival outcomes was assessed using univariate and multivariate Cox proportional hazards regression via the "coxph" function of the R survival package (v. 2.42.3). 19 We first tested the proportional hazards assumption for each covariate using the "cox.zph" function and found that none of the covariates violated the assumption, thus supporting the use of this model (Supporting Information Table S5 ). The fraction of each leukocyte subset in the sample was computed for the breast and ovarian cancer datasets using (1) CIBERSORT's LM22 mRNA leukocyte signature matrix, (2) our constructed miRNA leukocyte signature matrix, and (3) a combined mRNA-miRNA leukocyte signature matrix created by concatenating the LM22 and our miRNA signature matrices. Similar to the individual mRNA and miRNA signature matrices, in the combined mRNA-miRNA signature matrices, the columns correspond to the set of immune cells included in the analysis. Rows for the combined matrix include both genes and miRNAs from the individual signature matrices. In other words, this joint matrix is a concatenation of the two individual matrices. The relationship between immune cell infiltration in the samples and overall patient survival was then assessed. Following Gentles et al. 20 we used z scores to calculate the degree of statistical association between immune cell infiltration and survival outcomes as they effectively reflect both the directionality and robustness of the statistical association. A z score > 0 corresponds to a hazard ratio (HR) > 1, and z score < 0 corresponds to a HR < 1.
In addition to the univariate immune cell Cox regression analyses, we also examined multivariate Cox regression models using all 10 of the immune cell types in each dataset. We performed fivefold crossvalidation to both estimate immune cell composition in the tumor samples and to evaluate the performance of the Cox regression models.
For each train/test split (with 4/5 samples in the training set and 1/5 samples in the test set), we constructed and reduced a miRNA leukocyte signature matrix from the training set samples, and then used that signature matrix to estimate immune cell proportions in the test set samples. Next, we fit a Cox regression model relating patient survival and immune cell infiltration from the training set samples, and in turn used this model to predict survival outcomes for the test set samples.
Finally, we computed the survival concordance in the test set samples using all 10 of the immune cell types as predictors.
Source code available at https://github.com/mray/miRNAleukocyte-tumor-project.
3 | RESULTS
| Evaluating the constrained optimization method
We utilized preprocessed gene expression array, RNA-seq, miRNAseq, and survival data from TCGA breast and ovarian cancer datasets.
First, we used the mRNA expression data as input for CIBERSORT to estimate immune cell infiltration in the tumor samples. From the estimated immune cell proportions and miRNA expression data, we constructed miRNA profiles for 10 different immune cell types from each dataset. Since we expect miRNA levels to be non-negative, we did not use a standard deconvolution method for obtaining miRNA profiles for the different immune cell types. Instead, we used a constrained model in which we only allow the reconstructed values for each miRNA in each cell type to be non-negative. In our analysis, we observed a very small difference in the error between the unconstrained and constrained methods (Supporting Information Table S6 ).
For the breast cancer data, the unconstrained error was 1858, whereas the constrained error was 1874, resulting in a 0.9% proportional increase from the unconstrained to constrained model. For the ovarian cancer data, the unconstrained error was 1227 and the constrained error was 1233, yielding a 0.5% proportional increase between the two models. The small values for the proportional increase in reconstruction error indicate that it is indeed likely that the underlying values were positive and that these values were correctly inferred by our constrained optimization method.
| Assessing the consistency of the miRNAs selected for the immune cell signatures
We also tested the consistency of the miRNAs selected for each leukocyte subset signature. To this end, we performed cross-validation Figure S1 shows the consistency between the miRNA leukocyte signatures for the different cross-validation folds. We see that in the ovarian dataset, the miRNA leukocyte signature was perfectly consistent across all crossvalidation folds, highlighting the robustness of the approach. In the breast cancer dataset, while we observed a few miRNAs that were only selected for a subset of the folds, over 95% of the miRNAs selected for the signature matrices were shared across all folds, which again indicates that the method to construct the miRNA leukocyte signature matrices is robust to the random selection of patient samples.
| MiRNA leukocyte signature matrices
After validating the constrained optimization method and miRNA signature selection process, we constructed miRNA leukocyte signature matrices using the full set of samples in each dataset. The miRNA leukocyte signature matrix obtained from the breast cancer dataset contains 152 distinct miRNAs across 10 immune cell types (Supporting Information Table S7 ). To investigate the utility of integrating mRNA and miRNA leukocyte profiles, we combined our miRNA signature matrix with CIBERSORT's mRNA leukocyte signature matrix, LM22.
From the breast cancer data, the integrated mRNA-miRNA signature matrix contains a total of 699 genes and miRNAs across the 10 leukocyte subsets (Supporting Information Table S8 ). For the ovarian cancer dataset, the miRNA leukocyte signature matrix contains 83 distinct miRNAs across 10 immune cell types (Supporting Information Table S9 ). The ovarian combined mRNA-miRNA signature matrix contains 630 genes and miRNAs across the 10 leukocyte subsets (Supporting Information Table S10 ).
| Using mRNA and miRNA leukocyte signatures to infer the composition of tumors
We applied CIBERSORT's mRNA leukocyte signature matrix, LM22, our constructed miRNA signature matrix, and a combined mRNAmiRNA signature matrix to estimate the fractions of immune cell types within the tumor samples (Supporting Information Table S11 ). Using all three signatures, breast cancer samples generally contained high levels of macrophages M0 and M2, which generally agrees with prior work, with some sources estimating macrophages comprising as much as 40% of breast tumors. 21 The mRNA and combined mRNA-miRNA reported in prior work. 22 
| Prognostic associations of tumor-infiltrating immune cells
Immune cell infiltration in tumors has been associated with clinical outcomes in various cancers. TCGA provides not only mRNA and miRNA expression data, but also overall patient time-to-event survival information, enabling us to assess the relationship between immune cell infiltration in the tumor samples inferred by the three signature matrices (mRNA, miRNA, and combined mRNA-miRNA) and patient survival. We used univariate Cox regression to derive a z score for each immune cell type ( Figure 2 ). To account for multiple testing, we applied BenjaminiHochberg adjustments 23 at a false discovery rate (FDR) of 0.25 to identify the statistically significant prognostic associations.
In the breast cancer dataset, the combined mRNA-miRNA signature matrix yielded the most number of prognostically significant leukocyte subsets compared to the mRNA and miRNA signatures alone (seven leukocyte subsets were prognostically significant compared to five and three, respectively, Table 1 ). Overall, the M2 macrophage tumor fraction estimated using the miRNA signature emerged as the most significantly prognostic cell type with an adverse relationship to survival (z = 3.53, P = 4.22E−03).
In the ovarian cancer dataset, the combined mRNA-miRNA signature also yielded the most number of prognostically significant leukocyte subsets compared to the mRNA and miRNA signatures alone (seven, vs two and four, respectively, Table 1 ). The M1 and M2 macrophages were prognostically significant using all three signature matrices. The antiinflammatory M2 subtype was most significantly associated with poor survival using the mRNA signature (z = 3.73, P = 1.94E−4), whereas the pro-inflammatory M1 macrophages was most strongly associated with favorable survival using the miRNA signature (z = −2.81, P = 5.02E−3).
In addition to the univariate Cox regression analyses, we also examined multivariate Cox regression models using all 10 of the immune cell types in each dataset as described in the Section 2.3 above. We examined the survival concordance scores between the five cross-validation folds with each signature matrix (mRNA, miRNA, and combined mRNA-miRNA), both with real survival time/status for each sample, and after randomly shuffling survival time/status (with survival time and status reassigned in tandem). We compared the five cross-validation survival concordance values for each [signature matrix and survival vector] pair, using a one-sided t test to evaluate whether the miRNA and combined mRNA-miRNA signature matrices produced better survival concordance than either the mRNA signature matrix or the same signature matrix with shuffled survival data. Overall, we found that the survival concordance of our constructed miRNA and combined mRNA-miRNA signatures perform better than a random permutation of survival time and status, suggesting the discriminatory power of our constructed matrices ( Figure 3 , BRCA: P = 1.49E
−2 for miRNA, P = 4.21E−3 for mRNA-miRNA; OV: P = 4.75E−02 for miRNA, P = 4.42E−03 for mRNA-miRNA). Moreover, in the breast cancer data, the miRNA and combined signatures perform significantly better than the mRNA signature alone (P = 4.59E−2 and P = 2.15E −2, respectively). In the ovarian cancer data, there were no statistically significant differences between the signatures using the multivariate Cox regression model.
| Pathway associations of the most prognostically significant immune cell types
To investigate the association of M2 macrophages and miRNAs in breast cancer, we took the top ranked marker miRNAs of the M2 macrophage signature that we identified when constructing the refined miRNA signature matrix and inputted them into the target prediction tool DIANA-miRPath. 24 In brief, this tool takes a set of miRNAs as input and predicts the pathways targeted by the selected miRNAs. It then calculates a P value which denotes the extent that the pathway is enriched with gene targets of the selected miRNAs. Using this tool, we found that the TGF-β signaling pathway (P = 2.05E−02), metabolism of xenobiotics by cytochrome P450 (P = 1.80E−02) and phosphatidylinositol signaling system (P = 3.53E−02) are significantly enriched in the targets for the top five ranked miRNAs in the M2 macrophage signature. For the ovarian M1 macrophage signature, the Hippo (P = 5.69E−03), Ras (P = 4.74E−04), and mTOR (P = 1.42E−02) Abbreviations: BRCA, breast cancer; HR, hazard ratio; P, P value; CI, confidence interval; B-H, Benjamini-Hochberg; miRNA, microRNA; OV, ovarian cancer.
FIGURE 3
Survival concordance (A, breast cancer; B, ovarian cancer) for the mRNA, miRNA, and combined mRNA-miRNA signature matrices using multivariate cox regression models. The performance of our matrices was also compared to random permutations of survival time and status (shuffled)
signatures to characterize leukocyte infiltration in the tumor microenvironment in breast and ovarian cancer, and correlated the infiltration of the various immune cell types to patient survival.
We compared the association between immune cell infiltration and patient survival in breast and ovarian cancer using mRNA, miRNA, and combined mRNA-miRNA leukocyte signatures. In both datasets, Using the DIANA-miRPath tool, we found that the TGF-β pathway, a key pathway in the promotion of macrophages to the M2 phenotype, is one of the most significantly enriched pathways in gene targets for our top five ranked miRNAs in the M2 macrophage breast cancer signature (Supporting Information Figure S2 ). The selected miRNAs are predicted as regulators of SMAD2, as well as MAPK1 gene expression. While SMAD2 is a positive regulator of cell cycle arrest in the G1 phase, MAPK1 negatively regulates SMAD2. 35, 36 Thus, in the context of the M2 macrophage population, transcriptional silencing of the SMAD2 and MAPK1 genes by the selected miRNAs in the M2 macrophage signature are suggested to promote proliferation of the M2 macrophages in the tumor microenvironment.
In the ovarian cancer data, the prognostic association of the proinflammatory M1 macrophage cells was most significant using the miRNA signature, with a positive correlation with survival. The M1 macrophage phenotype is primarily activated by IFNγ and TNFα, and are generally reported to exert cytotoxic effects on cancer cells, [37] [38] [39] [40] [41] though specific knowledge of the homing mechanisms of M1 macrophages into the tumor microenvironment is lacking. We used the DIANA-miRPath tool to assess which molecular pathways are most significantly enriched for our top five ranked miRNAs for this cell type.
All five of the top ranked miRNAs for the M1 macrophage signature are implicated as regulating genes in the Hippo signaling pathway, which is a highly conserved signaling pathway that mediates cell proliferation and apoptosis (Supporting Information Figure S3 This approach can be applied to other cancers, with the goal of using these integrated mRNA and miRNA immune cell signatures in prognostic models to better predict patient outcomes, while also enabling the delineation of molecular mechanisms that underlie the relationship between miRNAs and tumor infiltrating immune cells in order to identify therapeutic targets within cancer-related pathways.
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